Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis
Jicheng Lv(Ministry of Education of the People's Republic of China), Vlado Perkovic(New South Wales Department of Health), Celine Foote(Tufts Medical Center), Hocine Tighiouart(Tufts University), Mark J. Sarnak(Tufts Medical Center), Giovanni FM Strippoli(The University of Sydney), Toshiharu Ninomiya(Kyushu University), Min Jun(New South Wales Department of Health), Haiyan Wang(Baylor College of Medicine), Anthony Rodgers(The George Institute for Global Health), Hong Zhang(Fudan University), Parya Ehteshami(Tufts Medical Center)
Cited by 307
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
|New England Journal of Medicine|2012|4.1k
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
|Circulation|2003|3.8k